Nicoletta Pella

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.

Alessandro Moretta, Alessandro Poggi, Daniela Pende et al. · The Journal of Experimental Medicine · 1991 · 213 citations · Full text

Life Sciences, Cell Biology, Immunology +11

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani et al. · Journal of Clinical Oncology · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

Marta Schirripa, Paola Biason, Sara Lonardi et al. · Clinical Cancer Research · 2019 · 107 citations · Full text

Medicine, Oncology, Pathology +17